India’s First DNA-Based Lung Cancer & Nicotine Dependence Test
Hyderabad, India — May 31, 2014 (World No Tobacco Day): MapmyGenome launched a new DNA-based Lung Cancer and Nicotine Dependence test on World No Tobacco Day.
The test decodes DNA, identifies specific changes in the genetic code, and assesses the genetic risk for lung cancer and nicotine dependence. It is recommended for people who have a history of smoking or exposure to environmental tobacco smoke.
“Our genetics-based lung cancer and nicotine dependence test is the culmination of requests from several key members of the medical community. This is our way of saying No to tobacco and Yes to oxygen.” — Anu Acharya, CEO, MapmyGenome
How the Test Works
The test uses single nucleotide polymorphism (SNP) genotyping of proven markers associated with lung cancer to study inherited and acquired changes in DNA that contribute to disease risk. The nicotine dependence markers allow users to understand their nicotine dependence pattern and formulate better smoking cessation plans.
Who Should Consider This Test?
Current or former smokers
Individuals with significant exposure to secondhand smoke
People with a family history of lung cancer
Anyone wanting to understand their genetic nicotine dependence to support quitting
Know Your Lung Cancer & Nicotine Risk Genetically
Genomepatri by MapmyGenome includes genetic insights into nicotine dependence and lung cancer risk — giving you and your doctor the information needed to build a personalised, more effective quit plan.
